Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;51(6):e13503.
doi: 10.1111/eci.13503. Epub 2021 Feb 12.

Bleeding events in lusutrombopag-treated thrombocytopenic patients

Edoardo Giovanni Giannini  1 , Takeshi Kano  2 , Toshimitsu Ochiai  3 , Roy Bentley  4 , Pomy Shrestha  5 , Nezam Afdhal  6
Affiliations

Bleeding events in lusutrombopag-treated thrombocytopenic patients

Edoardo Giovanni Giannini et al. Eur J Clin Invest. 2021 Jun.
No abstract available

Keywords: bleeding; invasive procedures; liver disease; platelets; thrombocytopenia.

PubMed Disclaimer

Conflict of interest statement

EGG is a consultant for Shionogi. TK, TO and RB are employees of Shionogi. PS was an employee of Shionogi at the time of the study. NA is a consultant/advisory board member for Gilead, Echosens, Ligand, Janssen, Shionogi, SpringBank and Trio Healthcare. NA has stock with SpringBank and Allurion and stock options with SpringBank.

Figures

FIGURE 1
FIGURE 1
Lusutrombopag mechanism of action. Thrombopoietin (TPO) acts on the TPO receptor, activates JAK and STAT pathways, and leads to an upregulation of megakaryocytes and platelet production. 16 Lusutrombopag triggers increased platelet production by activating signal transduction in a manner similar to endogenous TPO. 15 , 17 Adapted with permission from Kuter D. Int J Hematol 2013;98:10‐23
FIGURE 2
FIGURE 2
Patients with bleeding events (A), further subdivided by severity and timing of onset (B) (pooled safety data)a. LUSU, lusutrombopag; PBO, placebo. Pre‐procedural bleeding events are not shown. aPatients could be counted >1× in the same time period if they experienced 2 bleeding events with different severities but only 1× if severity was the same; the same patient could be counted >1× if they experienced bleeding events in different time periods
See this image and copyright information in PMC

References

    1. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther. 2006;23:1055‐1065. - PubMed
    1. Mitchell O, Feldman DM, Diakow M, Sigal SH. The pathophysiology of thrombocytopenia in chronic liver disease. Hepat Med. 2016;8:39‐50. - PMC - PubMed
    1. Giannini EG, Marenco S, Fazio V, Pieri G, Savarino V, Picciotto A. Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. Liver Int. 2012;32:1113‐1119. - PubMed
    1. Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI) . Hemostatic balance in patients with liver cirrhosis: report of a consensus conference. Dig Liver Dis. 2016;48:455‐467. - PubMed
    1. Giannini EG, Greco A, Marenco S, Andorno E, Valente U, Savarino V. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol. 2010;8:899‐902. - PubMed

MeSH terms

Grants and funding